ABCL AbCellera Biologics Inc.

11

Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]

CA | NASDAQ | Stock

Price
$7.54
Increased by +0.02%
Dollar Volume
11.78 M
ADR%
3.95
Earnings Report Date (estimate)
May 8, 23 (-0.14)
Market Cap.
2.17 B
Shares Float
209.15 M
Shares Outstanding
287.69 M
Beta
-0.09
Price / Earnings
14.50
BPR
5.57
20D Range
7.13 8.41
50D Range
7.13 11.38
200D Range
7.13 14.97
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 0.08
Increased by +900.00%
 0.05
Increased by +1.20 K%
Aug 9, 22 -0.02
Decreased by -105.41%
 -0.02
May 10, 22 0.54
Increased by +22.73%
 0.38
Increased by +110.80%
Nov 9, 21 -0.08 -0.05
Decreased by -1.20 K%
Aug 12, 21 -0.01 0.08
Decreased by -1.41 K%
May 13, 21 0.37 0.38
Decreased by -6.93%
Mar 29, 21 0.44 0.61
Decreased by -45.69%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 101.38 M
Increased by +1.74 K%
 26.62 M
Increased by +224.53%
Increased by +26.26%
Increased by +106.77%
Jun 30, 22 45.92 M
Increased by +66.11%
 -6.79 M
Decreased by -192.08%
Decreased by -14.78%
Decreased by -75.84%
Mar 31, 22 316.58 M
Increased by +56.15%
 168.57 M
Increased by +43.81%
Increased by +53.25%
Decreased by -7.90%
Dec 31, 21 139.33 M
Decreased by -32.98%
 59.95 M
Decreased by -48.76%
Increased by +43.03%
Decreased by -23.54%
Sep 30, 21 5.51 M
Decreased by -41.17%
 -21.38 M
Decreased by -693.91%
Decreased by -388.16%
Decreased by -1.25 K%
Jun 30, 21 27.64 M
Increased by +146.20%
 -2.32 M
Decreased by -134.66%
Decreased by -8.40%
Decreased by -114.08%
Mar 31, 21 202.74 M
Increased by +4.25 K%
 117.22 M
Increased by +5.70 K%
Increased by +57.82%
Increased by +228.65%
Dec 31, 20 207.91 M
Increased by +6.39 K%
 117.00 M
Increased by +7.23 K%
Increased by +56.27%
Increased by +209.82%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.